ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1571

Spatial Transcriptomics of Perivascular Subepidermal Regions in Very Early Systemic Sclerosis Unveils Cellular and Mitochondrial Stress-Driven Innate Immune Signatures that Initiate Stromal Remodeling

Ifeoluwa Emmanuel Bamigbola1, Jayakumar Vadakekolathu1, Stefano Di Donato2, Vishal Kakkar3, Rebecca Ross4, Yasser El-Sherbiny1 and Francesco Del Galdo3, 11Nottingham Trent University, Department of Biosciences, School of Science and Technology, Nottingham, United Kingdom, 2University of Leeds, Canosa Sannita, Chieti, Italy, 3University of Leeds, Leeds, United Kingdom, 4Medicine and Health, University of Leeds, Leeds, United Kingdom

Meeting: ACR Convergence 2025

Keywords: genomics, skin, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The skin from patients with Very Early Diagnosis of Systemic Sclerosis (VEDOSS) already exhibits fibrotic alterations such as collagen deposition and perivascular infiltration (1), despite the absence of clinically detectable skin thickening. A distinct immune-mediated structural organization across the epidermis, sub-epidermal region, and dermis, is involved in both early and late stages of SSc [2] The sub-epidermal perivascular area, located between these layers, serves as a crucial immune-fibro-vascular niche that may play a role in early fibrotic remodeling useful for determining SSc progression and identifying novel therapeutic applications.Objectives: To identify key signaling and cell types involved in the sub-epidermal perivascular regions within Very Early Diagnosis of Systemic Sclerosis (VEDOSS) compared to those with established disease and healthy control using spatial transcriptomic analyses.

Methods: We employed digital spatial transcriptomics to map whole genome transcriptome expression in the area immediately surrounding CD34-stained vessels in the sub-epidermal regions. Differentially expressed genes (p < 0.05, log2FC >0) were analyzed to identify relevant canonical pathways and biological processes.

Results: Six skin biopsies from VEDOSS were compared with six biopsies from healthy individuals or patients with developed systemic sclerosis (SSc). Cell deconvolution revealed that the sub-epidermal region was dominated by diverse fibroblast subsets and vascular endothelial cells, with notable representation of immune populations such as T cells and macrophages. Disease-associated shifts included early depletion of secretory papillary fibroblasts in VEDOSS, enrichment of lymphatic endothelial cells, and progressive erythrocyte loss. Pathway Analysis of the sub-epidermal region in VEDOSS compared to healthy controls revealed significant upregulation of key stress and immune-related pathways. Notable among these were Cellular response to hypoxia, Oxidative Phosphorylation, Neutrophil Degranulation, Mitochondrial Dysfunction, and pulmonary idiopathic fibrosis signaling pathway. Key genes significantly upregulated included cyclophilin A, CD47, ATP5MG, COX10, NDUFB9, S100A4, COL1A1, COL16A1, COL17A1, COL21A1, FN1, PIK3R2, PIK3C2B, PDGFRB, implying cellular remodeling and stromal transitions through associated signaling pathways involved in fibrosis.

Conclusion: We demonstrate that the sub-epidermal perivascular region is a transcriptionally dynamic niche in VEDOSS skin, where early immune, metabolic, and fibrotic reprogramming converges to initiate stromal remodeling before the onset of clinically detectable fibrosis and progression to SSc.References: [1] R[1] R. L. Ross et al., “Biological hallmarks of systemic sclerosis are present in the skin and serum of patients with Very Early Diagnosis of Systemic Sclerosis (VEDOSS),” Rheumatology, p. keae698, Dec. 2024, doi: 10.1093/rheumatology/keae698.[2] Z. Li et al., “Mapping spatially-resolved transcriptomes in systemic sclerosis,” bioRxiv, p. 2025.01.14.632962, Jan. 2025, doi: 10.1101/2025.01.14.632962.

Supporting image 1Ingenuity Pathway Analysis (IPA) of differentially expressed genes (DEGs) from the subepidermal region of interest (ROI), comparing VEDOSS with healthy controls. Pathways with an absolute z-score > 2 and p-value < 0.001 were considered significantly activated (z ≥ 2) or inhibited (z ≤ –2). Orange are predicted activated pathways and blue predicted inhibited.

Supporting image 2Representative examples of subepidermal regions of interest (ROIs) selected from the 54 ROIs analyzed.


Disclosures: I. Bamigbola: None; J. Vadakekolathu: None; S. Di Donato: None; V. Kakkar: None; R. Ross: None; Y. El-Sherbiny: None; F. Del Galdo: AbbVie/Abbott, 2, 5, argenx, 2, 5, AstraZeneca, 2, 5, Boehringer-Ingelheim, 2, 5, Calluna, 2, 5, Deepcure, 2, 5, Engitix, 2, 5, GlaxoSmithKlein(GSK), 2, 5, Janssen, 2, 5, Merck/MSD, 2, 5, Miltenyi, 2, 5, Mitsubishi-Tanabe, 2, 5, Novartis, 2, 5, Ono, 2, 5, Quell, 2, 5, RelationX, 2, 5, Serono, 2, 5, Syntara, 2, 5, Ventus, 2, 5, ZuraBio, 2, 5.

To cite this abstract in AMA style:

Bamigbola I, Vadakekolathu J, Di Donato S, Kakkar V, Ross R, El-Sherbiny Y, Del Galdo F. Spatial Transcriptomics of Perivascular Subepidermal Regions in Very Early Systemic Sclerosis Unveils Cellular and Mitochondrial Stress-Driven Innate Immune Signatures that Initiate Stromal Remodeling [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/spatial-transcriptomics-of-perivascular-subepidermal-regions-in-very-early-systemic-sclerosis-unveils-cellular-and-mitochondrial-stress-driven-innate-immune-signatures-that-initiate-stromal-remodeling/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/spatial-transcriptomics-of-perivascular-subepidermal-regions-in-very-early-systemic-sclerosis-unveils-cellular-and-mitochondrial-stress-driven-innate-immune-signatures-that-initiate-stromal-remodeling/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology